***Background.*** Evidence suggests that vancomycin has reduced effectiveness in MRSA bacteremia with higher vancomycin MIC values (\> 1 mg/L). However, clinical studies comparing vancomycin to alternative therapy in these patients are limited.

***Methods.*** We conducted a retrospective, nationwide, multicenter, matched (by age, bacteremia type, severity of illness, ID consult and institution), cohort study that compared daptomycin vs vancomycin among adult patients with MRSA bacteremia with high vancomycin MICs (1.5-2 mg/L). The primary outcome was composite failure, defined as having: 60-day all-cause mortality, 7-day clinical or microbiological failure, failure at end of therapy, and/or 30-day BSI relapse. Secondary outcomes included early bacteremia clearance by day 4 without recurrence and acute kidney injury (AKI). Stratified treatment-outcomes analyses by key baseline covariates were performed.

***Results.*** One hundred seventy patients from 11 United States institutions were included. The median daptomycin dose was 6 mg/kg (interquartile, IQ, range, 6-8 mg/kg). Daptomycin was dosed \>8 mg/kg in 26% (22/85). All patients had vancomycin troughs of at least 10 mg/L (median 17.5 mg/L; IQ range, 14.0-22.0 mg/L). Vancomycin troughs were \>15 mg/L in 71% (60/85). The primary composite endpoint did not vary between the daptomycin and vancomycin groups (31% vs 39%, respectively, P = 0.259). Both end of therapy failure and acute kidney injury were significantly lower in the daptomycin relative to the vancomycin group (11% vs 24%, respectively, P = 0.025, and 9% vs 23%, respectively, P = 0.043). In the stratified analyses, daptomycin demonstrated a higher rate of bacteremia clearance by day 4 than vancomycin (94% vs 56%, respectively, P = 0.035) among immunocompromised patients (n = 26).

***Conclusion.*** Results from this multicenter study provide real-world comparative data on the outcomes with daptomycin vs vancomycin in adult patients with MRSA bacteremia with vancomycin MIC 1.5-2 mg/L. As with all observational studies, these findings should be interpreted cautiously.
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